Protocol to evaluate the antiviral effect of FDA-approved drugs against dengue virus in Huh7 cells and AG129 mice.

Autor:	Palacios-Rápalo SN; Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico., Hernández-Castillo J; Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico., Cordero-Rivera CD; Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico., Benítez-Vega ML; Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico., De Jesús-González LA; Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas, Zacatecas, México., Reyes-Ruiz JM; Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional 'Adolfo Ruiz Cortines', Instituto Mexicano del Seguro Social (IMSS), Veracruz 91897, México; Facultad de Medicina, Región Veracruz, Universidad Veracruzana (UV), Veracruz 91700, México., Farfan-Morales CN; Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico; Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana (UAM), Unidad Cuajimalpa, Ciudad de México 05348, México., Osuna-Ramos JF; Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán 80019, México., Gonzalez-Gonzalez AM; Laboratorio de Ingeniería Tisular y Medicina Traslacional, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de Mexico (UNAM), Mexico City 54090, Mexico., Cruz R; Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico., Del Ángel RM; Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City 07360, Mexico. Electronic address: rmangel@cinvestav.mx.
Jazyk:	angličtina
Zdroj:	STAR protocols [STAR Protoc] 2024 Jun 21; Vol. 5 (2), pp. 102992. Date of Electronic Publication: 2024 Apr 02.
DOI:	10.1016/j.xpro.2024.102992
Abstrakt:	Finding an effective therapy against diseases caused by flaviviruses remains a challenge. Here, we present a protocol to test Food and Drug Administration-approved drugs that inhibit host nuclear protein import, promoting a reduction of dengue infection. We describe steps for analyzing the drug effect on nuclear import inhibition of cellular and viral proteins by confocal microscopy or western blotting. We then describe procedures for measuring the antiviral drug effects on virus-infected cells by flow cytometry and testing drug efficacy in dengue-infected AG129 mice by survival assays. For complete details on the use and execution of this protocol, please refer to Palacios-Rápalo et al. 1 . Competing Interests: Declaration of interests The authors declare no competing interests. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu